from web site
The pharmaceutical landscape in Germany has actually seen a substantial shift recently with the introduction and increasing appeal of GLP-1 (Glucagon-like peptide-1) receptor agonists. Initially established to treat Type 2 diabetes, medications like Ozempic and Wegovy have actually gotten international popularity for their weight loss effectiveness. For homeowners and migrants in Germany, comprehending the expense, reimbursement structure, and availability of these drugs is essential.
Germany operates under a special two-tier health care system consisting of statutory medical insurance (Gesetzliche Krankenversicherung or GKV) and private medical insurance (Private Krankenversicherung or PKV). This structure, integrated with rigorous federal guidelines on pharmaceutical rates, makes the cost of GLP-1 medications in Germany rather various from that in the United States or other European nations.
GLP-1 receptor agonists are a class of medications that simulate a natural hormonal agent in the body. They function by:
Typical GLP-1 medications offered in Germany include:
In Germany, the cost of a medication is extremely depending on whether it is being utilized for its main medical indicator (like Type 2 diabetes) or as a "lifestyle" treatment (like weight-loss).
If a client has Type 2 diabetes, the GKV generally covers the cost of medications like Ozempic or Rybelsus. In this case, the patient pays just a little co-payment (Zuzahlung), generally varying from EUR5 to EUR10 per prescription.
However, for weight management, the circumstance modifications. Under Section 20 of the Social Code Book V (SGB V), medications primarily intended for "enhancing the lifestyle" or weight reduction are currently left out from GKV protection. This suggests patients using Wegovy or Saxenda for weight-loss need to usually pay the complete list price out-of-pocket.
Private insurance companies have more flexibility. Depending on the specific tariff and medical requirement, some private insurance companies may reimburse the expense of weight-loss medications if the client fulfills particular criteria, such as a high BMI (normally >> 30 )and accompanying comorbidities (hypertension, sleep apnea).
The following table supplies a quote of out-of-pocket costs for the most popular GLP-1 medications in Germany as of late 2023/early 2024. Costs may differ a little between drug stores however are controlled by the Arzneimittelpreisverordnung (Medicines Price Ordinance).
| Medication | Main Usage | Form | Approx. Monthly Cost (Self-Pay) |
|---|---|---|---|
| Ozempic | Type 2 Diabetes | Weekly Injection | EUR80 - EUR90 |
| Wegovy (Low Dose) | Weight Loss | Weekly Injection | EUR170 - EUR190 |
| Wegovy (High Dose) | Weight Loss | Weekly Injection | EUR300 - EUR320 |
| Mounjaro | Diabetes/ Obesity | Weekly Injection | EUR260 - EUR330 |
| Saxenda | Weight-loss | Daily Injection | EUR250 - EUR300 |
| Rybelsus | Type 2 Diabetes | Daily Tablet | EUR100 - EUR140 |
Note: Costs represent the "Apothekenverkaufspreis" (Pharmacy Retail Price) for patients with a private prescription.
Wegovy was introduced in Germany in July 2023. Unlike the United States, where rates can go beyond ₤ 1,000 monthly, the German market gain from government-negotiated prices, though it remains costly for the average consumer.
The cost of Wegovy in Germany scales slightly with the dose. A basic 4-week supply includes one pen that enables four doses.
Typical Wegovy Price Tiers:
The disparity in between German and American drug prices is a regular subject of argument. The lower expenses in Germany are credited to:
No matter whether a patient is paying out-of-pocket or through insurance coverage, GLP-1 medications are prescription-only (verschreibungspflichtig).
Germany, like the remainder of the world, has actually faced significant shortages of Ozempic. Due to the fact that Ozempic is much less expensive than Wegovy (approx. EUR80 vs EUR170+), numerous patients looked for "off-label" prescriptions for weight reduction.
To fight this, the German Federal Institute for Drugs and Medical Devices (BfArM) has issued guidelines advising doctors to just recommend Ozempic for its authorized sign: Type 2 Diabetes. This is to guarantee that diabetic clients do not lose access to their life-saving medication.
Presently, no. Wegovy is categorized as a "lifestyle drug" in Germany. Regardless of recent conversations in the Bundestag regarding the increasing expenses of obesity, the statutory medical insurance funds are lawfully disallowed from covering obesity-only medications.
Yes. Any licensed pharmacy in Germany (including online drug stores like DocMorris or Shop Apotheke) can meet a private prescription for GLP-1 medications, offered they have the stock.
Yes, Mounjaro was just recently launched in the German market. It is readily available in the "KwikPen" format. Rates are currently greater than Ozempic but competitive with Wegovy's maintenance doses.
Beyond the medication, patients need to account for the expense of the physician's consultation. For GKV clients, this is covered. For private/self-pay patients, an assessment can cost in between EUR30 and EUR100 depending upon the complexity of the exam.
No. It is prohibited and highly dangerous to buy these medications without a prescription. Germany has rigorous laws versus "Fernabsatz" (mail order) of prescription drugs from non-certified sources. Fake Ozempic pens have actually been discovered in the European supply chain.
If you are considering GLP-1 treatment in Germany, keep the following points in mind:
The expense of GLP-1 medications in Germany shows the nation's more comprehensive method to healthcare: regulated, fairly budget friendly compared to the global market, but strictly separated in between medical need and optional treatment. While GLP-1-Injektionen in Deutschland gain from very low co-payments, those looking for these drugs for weight loss should be gotten ready for a considerable month-to-month investment. As clinical evidence continues to show the long-lasting health advantages of weight reduction, many in the German medical neighborhood wish for a shift in insurance coverage legislation that might one day make these treatments more accessible to all.
